Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Back in 1997, when mitoxantrone + prednisone became the first form of chemotherapy ever to be approved for the treatment of prostate cancer, the Southwest Oncology Group (SWOG) initiated a trial generally referred to as S9921 — and some of the results of this trial were presented at the annual meetings of the AUA and [...]
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation therapy, combined, survival | 1 Comment »
According to a media release from the Prostate Cancer Foundation yesterday, research at the University of Michigan Comprehensive Cancer Center suggests that the RAF oncogene that drives fatal forms of melanoma (an aggressive type of skin cancer) may also drive aggressive forms of prostate cancer.
Filed under: Diagnosis, Drugs in development, Risk, Uncategorized | Tagged: fusion, gene, oncogene, RAF | 5 Comments »
Us TOO International — one of the two oldest prostate cancer advocacy and support organizations in the world — will be celebrating its 20th birthday with a major event in Chicago on August 20 and 21 this year, and everyone is invited!
Filed under: Living with Prostate Cancer | Tagged: advocacy, Us TOO | 2 Comments »
At major medical meetings like the recent AUA and ASCO annual meetings (the latter wrapping up today in Chicago), what goes on in the conversations in the corridors and in private meetings is often more important and interesting than what is being presented from the podium or talked about at poster sessions.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, hormone refractory | 15 Comments »
There were a number of significant prostate cancer presentations today, and while none of them were “game changing” (for a variety of reasons), they are certainly worthy of notice.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, bevacizumab, cabazitaxel, external beam radiation, hormone therapy | 2 Comments »
One of the really “hot” pieces of news from ASCO today was the result of a Phase III clinical trial of ipilimumab in a form of metastatic skin cancer called melanoma. This is (perhaps) very important for prostate cancer patients.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, ipilimumab | Leave a Comment »
The recently announced GLOBOCAN 2008 assessment of the worldwide burden of cancer includes a global estimate of 258,000 deaths from prostate cancer in 2008, and a global incidence of 913,000 cases of prostate cancer that same year.
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: epidemiology, incidence, mortality | 7 Comments »
With the conclusion of the AUA annual meeting in San Francisco and the opening of the annual meeting of ASCO in Chicago, your correspondent has once again noted some core differences in the ways the oncology community and the urology community seem to approach their research agendas.
Filed under: Living with Prostate Cancer, Management | Tagged: agenda, priority, research | 1 Comment »
Data just published in Nature Biotechnology suggests that a new type of PSA test developed by a company called Quanterix is 1,700 times more sensitive than older, standard PSA detection methods used in clinical laboratories.
Filed under: Living with Prostate Cancer, Management, Risk | Tagged: PSA, Quanterix, sensitive, test | 3 Comments »
On Tuesday, the US Food and Drug Administration (FDA) approved Amgen’s RANK-L inhibitor denosumab (Prolia®) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. However, what they have not done (yet)
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: denosunam, fracture, Prevention, Prolia | Leave a Comment »
The most interesting thing about the educational process at the AUA this year is the increasing appreciation of the complexity of the decision-making processes required by patients and their doctors as regards prostate cancer risk and management.
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: decision-making, Diagnosis, Treatment | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site